All In Biotech

Drug Trial Radar · NCT02801097

RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD)

A Phase I, Open-Label, Multiple Ascending Dose Study to Assess the Safety and Tolerability of RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer Patients Without Life-Prolonging Therapies of Demonstrated Clinical Benefit (PAYLOAD)

Last checked: Nov 19, 2026Latest source record: May 17, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

28

Actual

Start

Aug 30, 2016

Primary completion

Nov 22, 2018

Study completion Dec 9, 2019

Sponsor

Lead sponsor
EpicentRx, Inc.Industry
Sponsor type
Industry
First posted
Jun 15, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 1 open-label trial to evaluate the safety, pharmacodynamics and clinical activity of RRx-001 administered in combination with irinotecan. RRx-001 is associated with resensitization to irinotecan in tumors that are previously refractory. This effect has been attributed to the ability of RRx-001 to restore the expression of aberrantly silenced genes, thus re-establishing pathway functions. However, resensitization may have more than one mechanism, among them Pgp pump inhibition and vascular modulation, leading to improved penetration of standard chemotherapy.

Conditions

  • Malignant Solid Tumor
  • Metastatic Cancer
  • Advanced Cancer

Interventions

  • RRx-001Drug

  • IrinotecanDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number, frequency and type of adverse eventsTime frame: 14 Weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • University of California, Davis

    Sacramento, California

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.